There have been no severe acute respiratory syndrome (SARS) cases since the end of the northern summer but worries are mounting of a recurrence in the winter season. "All the evidence points to a wild-animal source for the SARS coronavirus, but this source remains to be found. If the same set of circumstances occur this year in which the human population in southern China and north Vietnam is exposed again, we could certainly see more cases", comments Meirion Evans (University of Wales College of Medicine, Cardiff, UK), a member of the SARS Expert Committee.

Such fears are accelerating efforts to find a vaccine. In late November, the official Chinese news agency, Xinhua, reported an announcement by Yin Hongzhang, Head of the Biological Product Section of the Chinese State Food and Drug Administration, that clinical trials, in which healthy human volunteers will be given a "dead" strain of the SARS coronavirus, were close to being approved. Preclinical trials in monkeys have apparently shown the "dead" vaccine is effective without serious side-effects. The vaccine\'s developer, Beijing Kexing, Bioproduct Co, produced more than 20 000 doses in preparation for a 2-year study beginning at the end of 2003. In early December, the Canadian SARS Accelerated Vaccine Initiative also reported its intention to test a live vaccine and two recombinant vaccines within a year. Brett Finlay (University of British Columbia, Vancouver, Canada), director of the initiative, said that "human trials would be hurried to have a vaccine ready to go into production by spring 2005". "Things seems to be moving very fast", observes Evans, but warns against loss of last year\'s international cooperation. "Establishment of an international laboratory network led to the early identification of the causative organism of SARS, and it would be a great shame to forget this precedent", he says.

Research into why SARS caused so many deaths continues. In November, Zuo-Feng Zhang and Roger Detels (UCLA School of Public Health, Los Angeles, CA, USA) reported that analysis of publicly available data on SARS suggested a positive relation between SARS fatality and air pollution *(Environ Health* 2003; **2:** 15). "Although our study suggests that air pollution may increase the risk of dying from SARS, we were unable to investigate confounding factors such as exposure to smoking, occupational exposure to harmful substances, and the prevalence of pre-existing respiratory disease", comments Zhang. Detels adds that the next appropriate step to verify (or refute) this observed association would be to do studies that control for these factors. Evans agrees, pointing out that most cases of SARS in China occurred in urban areas, where pollution would tend to be higher. "The greatest risk factor for mortality did seem to be age and comorbidity", he says.
